Preliminary study of the efficacy and tolerability of combination therapy with calcipotriene ointment 0.005% and tacrolimus ointment 0.1% in the treatment of stable plaque psoriasis
- PMID: 23094314
Preliminary study of the efficacy and tolerability of combination therapy with calcipotriene ointment 0.005% and tacrolimus ointment 0.1% in the treatment of stable plaque psoriasis
Abstract
Calcipotriene ointment is widely used in the topical treatment of psoriasis, with tacrolimus ointment as an effective alternative in controlling stable plaque psoriasis. The efficacy of the combination of both products on stable plaque psoriasis has not been assessed in the literature consulted. We evaluated the efficacy of calcipotriene ointment 0.005% applied twice daily, tacrolimus ointment 0.1% applied twice daily, or a morning application of calcipotriene and an evening application of tacrolimus in 27 participants with stable plaque psoriasis over an 8-week treatment period. The mean reduction in the sum of the scores between baseline and week 8 was significant (P = .001) for calcipotriene alone (39.5%), tacrolimus alone (38.2%), and the combination of calcipotriene and tacrolimus (60.7%). Combination therapy was statistically more effective than tacrolimus alone (P = .043) but not statistically superior to calcipotriene alone (P=.056). Most adverse events (AEs) were related to skin irritation and pruritus; however, no AEs were evident in participants given the combination therapy.
Similar articles
-
A comparison of tazarotene 0.1% gel once daily plus mometasone furoate 0.1% cream once daily versus calcipotriene 0.005% ointment twice daily in the treatment of plaque psoriasis.Clin Ther. 2000 Oct;22(10):1225-38. doi: 10.1016/s0149-2918(00)83065-9. Clin Ther. 2000. PMID: 11110233 Clinical Trial.
-
Topical calcipotriene 0.005% and betamethasone dipropionate 0.064% maintains efficacy of etanercept after step-down dose in patients with moderate-to-severe plaque psoriasis: results of an open label trial.J Drugs Dermatol. 2011 Aug;10(8):878-82. J Drugs Dermatol. 2011. PMID: 21818509 Clinical Trial.
-
Comparison of cutaneous tolerance and efficacy of calcitriol 3 microg g(-1) ointment and tacrolimus 0.3 mg g(-1) ointment in chronic plaque psoriasis involving facial or genitofemoral areas: a double-blind, randomized controlled trial.Br J Dermatol. 2007 Nov;157(5):1005-12. doi: 10.1111/j.1365-2133.2007.08201.x. Br J Dermatol. 2007. PMID: 17935517 Clinical Trial.
-
Combined topical calcipotriene ointment 0.005% and various systemic therapies in the treatment of plaque-type psoriasis vulgaris: review of the literature and results of a survey sent to 100 dermatologists.J Am Acad Dermatol. 1997 Sep;37(3 Pt 2):S62-8. J Am Acad Dermatol. 1997. PMID: 9344188 Review.
-
Vitamin D and topical therapy.Cutis. 2002 Nov;70(5 Suppl):5-8. Cutis. 2002. PMID: 12467332 Review.
Cited by
-
Managing moderate-to-severe psoriasis in the elderly.Drugs Aging. 2014 Apr;31(4):233-8. doi: 10.1007/s40266-014-0156-6. Drugs Aging. 2014. PMID: 24554398 Review.
-
Tacrolimus for the management of psoriasis: clinical utility and place in therapy.Psoriasis (Auckl). 2016 Dec 7;6:153-163. doi: 10.2147/PTT.S101233. eCollection 2016. Psoriasis (Auckl). 2016. PMID: 29387602 Free PMC article. Review.
-
Sirolimus treatment for cirrhosis or hepatocellular carcinoma patients accompanied by psoriasis after liver transplantation: A single center experience.Oncol Lett. 2017 Dec;14(6):7817-7824. doi: 10.3892/ol.2017.7217. Epub 2017 Oct 18. Oncol Lett. 2017. PMID: 29344227 Free PMC article.
-
The Management of Plaque Psoriasis With Halobetasol and Tacrolimus Combination Therapy Versus Calcipotriol Monotherapy: A Case Report.Cureus. 2024 Jan 17;16(1):e52445. doi: 10.7759/cureus.52445. eCollection 2024 Jan. Cureus. 2024. PMID: 38371137 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical